Optimization of prediction of UC relapse and adjustment of adequate therapy in patient with ulcerative colitiss
https://doi.org/10.21886/2712-8156-2020-1-2-65-71
Abstract
Objective: to improve the assessment of activity of ulcerative colitis and the ability to predict the development of relapse of the disease, as well as the selection of adequate therapy.
Materials and methods: the study included 90 people: 70 patients with ulcerative colitis and 20 healthy volunteers. The disease activity was evaluated using 7 disease activity indices. The expression of matrix metalloproteinase -9 (MMP-9) in the colon mucosa was evaluated by immunohistochemistry.
Results: data were obtained on the activity of MMP-9 in colonobioptates in patients with ulcerative colitis with varying degrees of disease severity, which complements our knowledge of the pathogenetic mechanisms of UC and, based on the developed mathematical model, allows predicting the development of recurrence of UC. Based on the analysis of clinical indices of UC activity, an algorithm for evaluating the effectiveness of basic therapy has been developed.
Conclusion: tools are provided to improve the prognosis of UC relapse, and a personalized approach to evaluating the effectiveness of the alternatives of drug therapy is developed.
About the Authors
A. V. Tkachev
Rostov State Medical University
Russian Federation
Russian Federation
Alexander V. Tkachev, Dr. Sci. (Med.), Prof., head of propaedeutics of internal disease
Rostov-on-Don
K. E. Mazovka
Rostov State Medical University
Russian Federation
Russian Federation
Karina E. Mazovka, Cand. Sci. (Med.), Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
L. S. Mkrtchyan
Rostov State Medical University
Lilit S. Mkrtchyan, Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
A. S. Makarenko
Rostov State Medical University
Artem S. Makarenko, Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
L. T. Takidze
Rostov State Medical University
Liya T. Takidze, Assistant Professor of department of propaedeutics of internal disease
Rostov-on-Don
References
1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. https://doi.org/10.1016/S0140-6736(16)32126-2.
2. Danese S., Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-1725. https://doi.org/10.1056/NEJMra1102942
3. Рахимова О.Ю., Юрков М.Ю., Митрофанова И.П., Пайзуллаева З.К., под ред. Комаров Ф.И., Рапопорт С.И. Воспалительные заболевания кишечника. Руководство по гастроэнтерологии. Москва, 2010.
4. Каграманова А. В., Михайлова С. Ф., Князев О. В., Фадеева Н.А., Лищинская А.А., Парфенов А.И. Внекишечные проявления воспалительных заболеваний кишечника. Терапия. 2017;4(14):107-118. eLIBRARY ID: 29771052
5. Ravi A., Garg P., Sitaraman S.V. Matrix Metalloproteinases in IBD: boon or bane? Inflamm Bowel Dis. 2007;13(1):97-107. https://doi.org/10.1002/ibd.20011
6. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955; 2(4947):1041- 1048. https://doi.org/10.1016/s1578-1550(09)71172-6.
7. Huber S. New insights into inflammatory bowel disease – 1st ed. – InTech, 2016; 264. URL: https://www.intechopen.com/books/new-insights-into-inflammatory-bowel-disease (date of access 12.08.2019). – Еlectronic text.
8. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 2004;113(10):1490-7. https://doi.org/10.1172/JCI19836.
9. Sanchez-Muñoz F., Dominguez-Lopez, A., Yamamoto-Furusho J. K. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280-4288 https://doi.org/10.3748/wjg.14.4280.
10. Rachmilewitz, D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298 (6666):82-86. https://doi.org/10.1136/bmj.298.6666.82.
11. Левитан М. Х., Федоров В. Д., Капуллер Л. Л.. Неспецифические колиты. Москва. Медицина. 1980:
12. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987;317(26) 1625-1629. https://doi.org/10.1056/NEJM198712243172603.
Review
For citations:
Tkachev A.V., Mazovka K.E., Mkrtchyan L.S., Makarenko A.S., Takidze L.T. Optimization of prediction of UC relapse and adjustment of adequate therapy in patient with ulcerative colitiss. South Russian Journal of Therapeutic Practice. 2020;1(2):65-71. (In Russ.) https://doi.org/10.21886/2712-8156-2020-1-2-65-71
Views:
652
Email this article 